Osimertinib + Savolitinib for carcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Sep 2020: Trial started, NCT04606771
  2. 28 Oct 2020: Trial registered, NCT04606771

The trials

NCT04606771: A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

State
Under way
Phase
Phase 2
People
30 taking part
Started
28 Sep 2020
Primary completion
21 Dec 2022
Arms
Arm A
Results
Posted on the registry
  1. 28 Sep 2020: Trial started
  2. 28 Oct 2020: Trial registered
  3. 24 Sep 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.